Novartis to Work With Amgen on Alzheimer’s and Migraine DrugsBy
Swiss giant targets treatments for neurological conditions
Amgen to make upfront payment, milestones on Alzheimer's
Novartis AG said it formed a partnership with California biotechnology company Amgen Inc. to develop new drugs for Alzheimer’s disease and migraines, the latest step in the Swiss drugmaker’s plan to build a portfolio of treatments for neurological illnesses.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.